Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

Archives of Internal Medicine

Volumn 160, Issue 9, 2000, Pages 1321-1326

  Heymsfield, Steven B ^a,f   Segal, Karen R ^b   Hauptman, Jonathan ^b   Lucas, Charles P ^b   Boldrin, Mark N ^b   Rissanen, Aila ^c   Wilding, John P H ^d   Sjöström, Lars ^e  

^a St Luke's Roosevelt Hospital Center ^*  (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0034621494     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.9.1321     Document Type: Article

References (24)

1. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment ot overweight and obesity in adults: executive summary. Am J Clin Nutr. 1998;68:899-917.
2. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481-486.
3. World Health Organization. The World Health Report, 1997: Conquering Suffering, Enriching Humanity. Geneva, Switzerland: World Health Organization; 1997.
4. Fuller JH. Mortality trends and causes of death indiabetic patients. Diabetes Metab. 1993;19:96-99.
5. Wing R, Blair E, Bononi P, Marcus M, Watanabe R, Bergman R. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care. 1994; 17:30-36.
6. Watts NB, Spanheimer RG, Digirolamo M, et al. Prediction of glucose response to weight loss in patients with non-insulin dependent diabetes mellitus. Arch Intern Med. 1990;150:803-806.
7. Williamson D. Intentional weight loss: patterns in the general population and its association with morbidity and mortality. Int J Obes Relat Metab Disord. 1997; 21(suppl 1):S14-S19.
8. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-242
9. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167-173.
10. Hauptman J, Lucas C, Boldrin MN, Collins H, for the Orlistat Primary Care Study Group, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-167.
11. Diabetes mellitus: report of a WHO study group. World Health Organ Tech Rep Ser. 1985;727:1-113.
12. Shaw JE, Zimmet PZ, de Courten M, et al. Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes in Mauritius? Diabetes Care. 1999;22:399-402.
13. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996:276:637-639.
14. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York, NY: McGraw-Hill Co; 1971.
15. Agresti A. Categorical Data Analysis. New York, NY: John Wiley & Sons Inc; 1990.
16. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett PH. A twostep model for development of non-insulin-dependent diabetes. Am J Med. 1991; 90:229-235.
17. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med. 1988; 319:1500-1506.
18. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701-710.
19. Despres J, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
20. Landsberg L. Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension. 1992;19(1 suppl):161-166.
21. Wing R, Venditti E, Jakicic J, Polley B, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care. 1998;21: 350-360.
22. Long SO, O'Brien K, MacDonald KG, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. Diabetes Care. 1994;17:372-375.
23. Bray GA. Coherent, preventive and management strategies for obesity. Ciba Found Symp. 1996;201:228-246
24. Diabetes Prevention Program Research Group. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.